Dr. Andrew Cheng joined Akero in September, 2018, as President and Chief Executive Officer. Prior to joining Akero, Andrew served Gilead Sciences’ Senior Vice President from 2009-2015, then became Executive Vice President and Chief Medical Officer, during which time, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology, and biometrics), which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV, and liver diseases.
Andrew previously served on the board of directors of Syntimmune, Inc., which was acquired by Alexion, and in August 2019, joined the board of directors of Arbutus Biopharma Corporation. He holds a BA in biology from Johns Hopkins University, and an MD and PhD in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA, and was board certified in internal medicine.